Baxter International Inc. (NYSE:BAX) Receives $28.89 Consensus Price Target from Analysts

Baxter International Inc. (NYSE:BAX) has earned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $28.8889.

A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, October 8th. Stifel Nicolaus reiterated a “hold” rating and issued a $25.00 price target (down from $36.00) on shares of Baxter International in a research report on Monday, August 4th. Wells Fargo & Company cut their price target on shares of Baxter International from $33.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Morgan Stanley cut their price target on shares of Baxter International from $28.00 to $27.00 and set an “underweight” rating on the stock in a research report on Tuesday, July 15th. Finally, The Goldman Sachs Group downgraded shares of Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 price target on the stock. in a research report on Friday, August 1st.

Hedge Funds Weigh In On Baxter International

Hedge funds have recently made changes to their positions in the business. Zions Bancorporation National Association UT bought a new position in Baxter International during the first quarter worth $27,000. Rossby Financial LCC acquired a new stake in shares of Baxter International during the first quarter worth $29,000. CoreFirst Bank & Trust acquired a new stake in shares of Baxter International during the second quarter worth $27,000. Creative Financial Designs Inc. ADV lifted its holdings in shares of Baxter International by 169.6% during the second quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 619 shares in the last quarter. Finally, MTM Investment Management LLC acquired a new stake in shares of Baxter International during the second quarter worth $30,000. 90.19% of the stock is owned by institutional investors.

Baxter International Stock Performance

Baxter International stock opened at $23.08 on Wednesday. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30. Baxter International has a 1 year low of $21.33 and a 1 year high of $37.74. The company has a market cap of $11.85 billion, a PE ratio of -76.92, a PEG ratio of 0.75 and a beta of 0.58. The company’s 50-day moving average is $23.54 and its two-hundred day moving average is $27.38.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.01). Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The business had revenue of $2.81 billion for the quarter, compared to analyst estimates of $2.82 billion. During the same quarter in the previous year, the company posted $0.68 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. Equities analysts anticipate that Baxter International will post 2.48 earnings per share for the current year.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.